Journal de l'hypertension : accès libre

Resistance exercise is known to influence cardiovascular responses, with Systolic Blood Pressure (SBP) being a key indicator of cardiovascular strain. Traditional training protocols often emphasize specific rest intervals between sets to optimize performance and recovery. However, the impact of different rest intervals on the systolic pressure response during resistance exercise remains underexplored. This study investigates the effect of rest interval duration on the V-shape systolic pressure response, which is typically observed with conventional rest periods. We compared the systolic pressure responses during resistance exercise with short versus extended rest intervals to determine if the V-shape response is maintained or diminished. Our findings indicate that extended rest intervals do not preserve the traditional V-shape SBP response observed with shorter intervals, suggesting that rest interval length may play a significant role in cardiovascular adaptations to resistance training. These insights could inform training protocols and cardiovascular risk assessments for individuals engaging in resistance exercise.

Bartter Syndrome is a genetic disorder characterized by a set of renal tubulopathies that result in electrolyte imbalances, metabolic alkalosis and impaired blood pressure regulation. A key protein involved in this condition is the Na-K-2Cl Cotransporter 2 (NKCC2), which plays a crucial role in renal salt reabsorption. Proper functioning and regulation of NKCC2 are essential for maintaining electrolyte balance and normal blood pressure. This abstract reviews the role of protein quality control mechanisms in the regulation of NKCC2 and their implications for Bartter Syndrome and blood pressure homeostasis. We explore how mutations or dysfunctions in these quality control processes can lead to altered NKCC2 function, contributing to the clinical manifestations of Bartter Syndrome. By integrating recent research findings, this review aims to elucidate the complex interplay between protein quality control and NKCC2 activity and how these interactions impact blood pressure regulation.

Hypertension, a prevalent cardiovascular condition, significantly contributes to organ damage, affecting vital organs such as the heart, kidneys and brain. The early detection of hypertension-mediated organ damage is crucial for timely intervention and prevention of further complications. Plasma biomarkers have emerged as valuable tools in this context, offering a non-invasive method to monitor and assess the extent of organ damage. This comprehensive review examines the current state of research on plasma biomarkers associated with hypertension-induced organ damage. It highlights the roles of various biomarkers, including those related to inflammation, oxidative stress and endothelial dysfunction, in the detection and progression of organ damage. The review also discusses the potential for integrating these biomarkers into clinical practice for improved diagnosis and management of hypertension-related complications. By synthesizing recent findings and identifying gaps in the current knowledge, this review aims to provide a foundation for future research and development of diagnostic and therapeutic strategies in hypertension care.

Hypertension is both a cause and consequence of Chronic Kidney Disease (CKD), significantly accelerating its progression and increasing morbidity and mortality. Accurate Blood Pressure (BP) measurement and management are critical for mitigating these risks. This review examines the complex pathophysiology of hypertension in CKD and evaluates current BP management guidelines, including the 2017 AHA/ACC and 2021 KDIGO recommendations. Emphasis is placed on the importance of individualized treatment plans incorporating lifestyle modifications, RAAS inhibitors, calcium channel blockers, diuretics, and novel agents such as SGLT2 inhibitors. The review also explores emerging pharmacological therapies and their potential benefits. Effective BP control in CKD patients not only slows disease progression but also reduces cardiovascular risk, underscoring the need for a patient-specific approach to optimize clinical outcomes. Further research is required to refine treatment protocols and enhance therapeutic efficacy in this high-risk population.